01.06.2022 • News

Bakelite Synthetics Buys Georgia-Pacific Chemicals

Bakelite Synthetics – formerly part of US resins producer Hexion – has closed its purchase of Georgia-Pacific Chemicals. Financial terms were not disclosed.

The acquisition gives Bakelite complementary resin and formaldehyde technology and end markets in the building materials, transportation, industrial, chemical intermediate and specialty resins space, as well as 11 chemical facilities employing about 600 people in the US and South America.

“We are excited about the opportunities that will result from the combined strengths of the two companies,” said Bakelite CEO JP Aucoin. “This acquisition enables us to deliver greater value to our customers through a broader product offering and expanded geographic reach. It also enables us to deliver on significant organic growth with the strong tailwinds in US residential construction.”

The combined company’s new headquarters will be based in Atlanta, Georgia – Bakelite’s former base was in Louisville, Kentucky – and will consist of approximately 1,500 employees and 21 manufacturing sites in 10 countries.

Bakelite was formed on May 1, 2021, from the $425 million purchase of Hexion’s phenolic resins business by private equity firms Black Diamond and Investindustrial.

Author: Elaine Burridge, Freelance Journalist

Photo by Patrick Schätz on Unsplash
Photo by Patrick Schätz on Unsplash

Company

Logo:

Bakelite Synthetics

1040 Crown Pointe Parkway
30338 Atlanta
US

Company contact







Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read